Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: Evidence from Belgian prescription data

European Journal of Health Economics

Volumn 13, Issue 3, 2012, Pages 301-313

  Farfan Portet, Maria Isabel ^a   Van De Voorde, Carine ^a   Vrijens, France ^a   Stichele, Robert Vander ^b  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Belgium; Cost sharing; Pharmaceuticals; Reference pricing; Reimbursement; Socioeconomic factors

Indexed keywords

ACETYLCYSTEINE; BISOPROLOL; CITALOPRAM; CLARITHROMYCIN; DILTIAZEM; FUROSEMIDE; GENERIC DRUG; GLICLAZIDE; LANSOPRAZOLE; PIROXICAM; THIAZIDE DIURETIC AGENT; TRAMADOL;

ARTICLE; BELGIUM; DRUG COST; DRUG USE; EDUCATIONAL STATUS; EMPLOYMENT; GENERAL PRACTITIONER; GEOGRAPHY; GERIATRIC PATIENT; HUMAN; INCOME; NURSING HOME; PATIENT ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT;

ADOLESCENT; ADULT; AGED; BELGIUM; CHOICE BEHAVIOR; COST SHARING; DRUGS, GENERIC; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHARMACIES; PRESCRIPTION DRUGS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84861124600     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0377-8     Document Type: Article

References (41)

1. Vogler, S., Habl, C., Leopold, C., Rosian-Schikuta, I., de Joncheere, K., Thomsen, T.L.: PPRI Report. In. Gesundheit Ö sterreich GmbH, (2008)
2. Lopez-Casasnovas, G., Puig-Junoy, J.: Review of the literature on reference pricing. Health Policy 54(2), 87-123 (2000)
3. Dickson, M., Redwood, H.: Pharmaceutical reference prices. How do they work in practice? PharmacoEconomics 14(5), 471-479 (1998) (Pubitemid 28512061)
4. Narine, L., Senathirajah, M., Smith, T.: Evaluating referencebased pricing: initial findings and prospects. Can. Med. Assoc. J. 161(3), 286-288 (1999) (Pubitemid 29397263)
5. Aaserud, M., Dahlgren, A.T., Kosters, J.P., Oxman, A.D., Ramsay, C., Sturm, H.: Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst. Rev. 2(2), CD005979 (2006)
6. Danzon, P.M., Ketcham, J.D.: Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Front Health Policy Res 7, 1-54 (2004)
7. Puig-Junoy, J.: What is required to evaluate the impact of pharmaceutical reference pricing? Appl Health Econ Health Policy 4(2), 87-98 (2005) (Pubitemid 41324094)
8. Brekke, K.R., Konigbauer, I., Straume, O.R.: Reference pricing of pharmaceuticals. Journal of Health Economics 26(3), 613-642 (2007) (Pubitemid 46560149)
9. Vrijens, F., Van de Voorde, C., Farfan-Portet, M.I., le Polain, M., Lohest, O.: The reference price system and socioeconomic differences in the use of low cost drugs. In: Health Services Research (HSR), vol. 126B. Belgian Health Care Knowledge Centre (KCE), Brussels (2010)
10. Goldman, D.P., Joyce, G.F., Zheng, Y.: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. Jama 298(1), 61-69 (2007) (Pubitemid 47026771)
11. Morgan, S., Hanley, G., Greyson, D.: Comparison of tiered formularies and reference pricing policies: a systematic review. Open Med 3(3), e131-139 (2009)
12. Benda, J., Thorre, K.: Evaluation économique de la consommation des médicaments 2003-2006. In: Une étude des mutualités libres, p. 35. Mutualités Libres (2007)
13. Cornelis, K.: L'évolution des dépenses de soins de santé en Belgique. Une dynamique entre la maîtrise des dépenses publiques et la protection financière du patient. In: Dossier thématique MC, p. 112. Mutualité Chrétienne, Bruxelles (2006)
14. Cornelis, K.: L'influence des mesures prises dans le secteur des spécialités pharmaceutiques ambulatoires remboursables, sur l'évolution des dépenses et des volumes. In: MC-Informations, vol. 230, p. 12. Mutualités Chretiennes, Bruxelles (2007)
15. Diels, J.: Vers des prescriptions qui tiendraient (davantage) compte du coût des médicaments? Les médicaments géné riques dans un cadre plus large, p. 23. Mutualités Chrétiennes, Bruxelles (2004)
16. Laasman, J.-M., Lange, B.: Impacts financiers du remboursement de référence. Une actualisation. In: Etude, p. 29. Bruxelles (2006)
17. Laasman, J.-M., Lange, B.: Impacts financiers du remboursement de référence. Une actualisation. In: Etude, p. 29. Bruxelles (2008)
18. Laasman, J.-M., Lange, B.: Impacts financiers du remboursement de référence. Une actualisation. In: Etude, p. 26. Bruxelles (2009)
19. Brekke, K.R., Holmas, T.H., Straume, O.R.: Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment. Journal of Public Economics 95(7-8), 624-638 (2011)
20. Schneeweiss, S., Soumerai, S.B., Glynn, R.J., Maclure, M., Dormuth, C., Walker, A.M.: Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. Can. Med. Assoc. J. 166(6), 737-745 (2002) (Pubitemid 34253122)
21. Schneeweiss, S., Soumerai, S.B., Maclure, M., Dormuth, C., Walker, A.M., Glynn, R.J.: Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin. Pharmacol. Ther. 74(4), 388-400 (2003) (Pubitemid 37222860)
22. Schneeweiss, S., Walker, A.M., Glynn, F.J., Maclure, M., Dormuth, C., Soumerai, S.B.: Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 346(11), 822-829 (2002) (Pubitemid 34984656)
23. Fuchs, V.R.: Reflections on the socio-economic correlates of health. Journal of Health Economics 23(4), 653-661 (2004) (Pubitemid 39140302)
24. Grossman, M.: On the concept of health capital and the demand for health. J Polit Econ 80(2), 223 (1972)
25. Cutler, D.M., Lleras-Muney, A.: Understanding differences in health behaviors by education. Journal of Health Economics 29(1), 1-28 (2010)
26. Le Polain, M., Franken, M., Koopmanschap, M., Cleemput, I.: Drug reimbursement systems: international comparison and policy recommendations. In: Health Services Research (HSR), vol. 147B. Belgian Health Care Knowledge Centre (KCE), Brussels (2010)
27. Corens, D.: Health system review: Belgium. Health Systems in Transition 9(2), 1-172 (2007)
28. World Health Organization: ATC structure and principles (2010)
29. Pharmaceutical Policy Management Unit Health Care Department: Global analytical report on the content of Pharmanet - singular pathway. INAMI/RIZIV, (2010)
30. Simoens, S., De Bruyn, K., Bogaert, M., Laekeman, G.: Pharmaceutical policy regarding generic drugs in Belgium. PharmacoEconomics 23(8), 755-766 (2005) (Pubitemid 41420423)
31. Soins de Santé: Prescription en dénomination commune internationale (DCI). INAMI/RIZIV, Brussels (2006)
32. INAMI/RIZIV: Prescription de médicaments : le nombre de médicaments délivrés en DCI en augmentation constante. http://www.riziv.be/news/fr/press/pdf/press20100506.pdf (2010). Accessed 27 Oct 2010
33. Vander Stichele, R., Bogaert, M.: Prescriptions en DCI: Propositions pour l'implémentation pratique dans la pratique médicale et dans le dossier médical électronique. Centre belge d'information pharmacothérapeutique et Agence fédérale des médicaments et des produits de santé Brussels (2010)
34. SPF Economie, P.M.E., Classes moyennes & Energie: Enquête socio-économique générale 2001. In: Carrefour de l'Economie, vol. 6, p. 20.
35. SPF Economie, P.M.E., Classes moyennes & Energie (2003) Unesco: International Standard Classification of Education (ISCED) -1997. Unesco (2006)
36. Wooldridge, J.: Econometric Analysis of Cross Section and Panel Data. MIT Press Cambridge, MA (2002)
37. Lundin, D.: Moral hazard in physician prescription behavior. Journal of Health Economics 19(5), 639-662 (2000)
38. Coscelli, A.: The importance of doctors' and patients' preferences in the prescription decision. The Journal of Industrial Economics 48(3), 349-369 (2000)
39. Hellerstein, J.K.: The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ 29(1), 108-136 (1998) (Pubitemid 128351561)
40. Annemans, L., Closon, J.-P., Closon, M.-C., Heymans, I., Lagasse, R., Mendes da Costa, E., Moureaux, C., Roch, I.: Comparison of the cost and the quality of two financing systems of primary health care in Belgium. In: Health Services Research (HSR), vol. 85B. Belgian Health Care Knowledge Centre (KCE), Brussels (2008)
41. Towse, A.: The efficient use of pharmaceuticals: does europe have any lessons for a medicare drug benefit? Health Aff. 22(3), 42-45 (2003) (Pubitemid 41388742)